In a dramatic move on June 9, 2025, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. dismissed all 17 members of the CDC’s Advisory Committee on Immunization Practices (ACIP), the key body advising the federal government on vaccine safety and immunization policies. The action has sent shockwaves through the public health and vaccine development communities, raising concerns about regulatory continuity and future vaccine rollouts, according to GlobalData.

GlobalData’s latest Bio/Pharmaceutical Outsourcing Report notes that this leadership overhaul at ACIP could disrupt vaccine R&D pipelines and delay approvals of new immunizations. Kathryn Kinch, Senior Pharma Product Manager at GlobalData, stated, “These sudden changes at ACIP may lead to regulatory uncertainty for vaccine developers and manufacturers, possibly delaying market access and decision-making around new vaccine introductions.”

Simultaneously, the report highlights Antibody-Drug Conjugates (ADCs) as the fastest-growing segment in the biopharma innovation pipeline for 2025. This rapid expansion is being supported by a wave of strategic investments and manufacturing partnerships to scale ADC production, particularly for oncology applications.

“Despite only 6% of ADCs currently being marketed, the demand is projected to soar over the next decade,” said Katarina Zahedi, Pharma Analyst at GlobalData. “With rising interest in reshoring pharmaceutical manufacturing and looming U.S. tariffs, ADC-related clinical and commercial manufacturing contracts are expected to climb.”

The Bio/Pharmaceutical Outsourcing Report also tracks emerging regulatory changes, recent M&A activity, contract manufacturing agreements, and new financing developments for CDMOs. While ADC innovation signals opportunity, the ACIP reshuffle introduces an element of unpredictability into the U.S. vaccine landscape that stakeholders will closely monitor in the months ahead.